Skip to main content

Table 2 Adverse events. All adverse events at least possibly attributed to study treatment are shown. Numbers represent the number of patients per arm experience a particular event at any point during the treatment period, with the highest grade reported for any single individual. Adverse event grade is according to NCI CTCAE v.3

From: Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

  Grade 1 Grade 2 Grade 3–5
Arm 1 Arm 2 Arm 1 Arm 2 Arm 1 Arm 2
General / Constitutional
 Chills 3 (33%) 1 (11%)   1 (11%)   
 Fatigue 2 (22%) 2 (22%)   1 (11%)   
 Fever 1 (11%) 1 (11%)     
 Malaise   1 (11%)     
 Pain   2 (22%)     
 Headache   3 (33%)     
 Injection site reaction   6 (67%)     
Gastrointestinal
 Nausea 3 (33%) 3 (33%)     
 Diarrhea   1 (11%)     
Vascular
 Hypertension 1 (11%)      
 Hot flashes   1 (11%)     
Hematologic
 Anemia   1 (11%)     
Metabolism
 Anorexia   1 (11%)     
Musculoskeletal
 Arthralgia   1 (11%)     
 Back pain     1 (11%)   
 Myalgia   1 (11%)     
 Pain in extremity   1 (11%)